SBIR/STTR Research Award
Electrical Biosensor for Rapid Point-of-Care Diagnosis of Urinary Tract Infections and Antibiotic Susceptibility Testing
Award amount
$225,000Program and phase
SBIR · Phase IAward year
2016Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Avails Medical, Inc.
- Proposal award date
- 2016-07-01
- Contract end date
- 2016-12-31
- UEI
- HLMPAGQWHTL1
- Solicitation number
- PA15-269
- Topic code
- NIAID
Research abstract
Project Summary
Every year over million people are diagnosed with urinary tract infections UTIandapos s in the United States alone
UTIandapos s encompass bacterial infiltrations of the urinary tract and the most common bacterial infections worldwide
Together with the increasing threat of antimicrobial resistance and the lengthy diagnosis time physicians are in
need of technology that allows for rapid bacterial identification and their susceptibility to antibiotics at the point
of care
Todayandapos s gold standard for point of care UTI diagnosis is dipstick testing a calorimetric test strip that changes
colors if bacterial and leukocyte metabolites are present in a urine sample However the sensitivity and
specificity of dipsticks for those UTI markers are poor For accurate diagnosis and antibiotic susceptibility
testing urine samples are sent for laboratory bacterial cultures a process that takes up to three days
To bring rapid and accurate UTI diagnosis and antibiotic susceptibility testing to the point of care we are
developing a device that uses a silicon nanowire field effect transistor SiNW ISFET to detect protons
produced upon bacterial metabolism In the device bacteria from clinical urine samples are captured and
concentrated on a filter that is in liquid contact with the sensor Exposing the captured bacteria to a carbon
source containing media with low buffering capacity and incubating at C we are able to detect bacterial
infections CFU ml by a significant pH change of the media and in as low as minutes discriminate
Gram types by selective dye based inhibition of proton production by Gram positive bacteria and detect
antibiotic susceptibility and resistance when bacteria were exposed to the drugs The three specific aims of this
proposal address the optimization of the three assays and their validation in de identified clinical urine samples
We will determine the accuracy of our technology by comparing our results with the laboratory gold standards
including urine dipstick disk diffusion broth dilution and microscopic gram staining Project Narrative
In the United States every year over million people are diagnosed with urinary tract infections UTIs the
most common bacterial infections worldwide In addition bacterial resistance to antibiotics is an increasing
health threat hence non targeted antibiotic treatments not only result in unknown therapy outcome for the
patients but also promote further formation of antimicrobial resistance One major problem today is the long
diagnosis times of an infection together with the identification of an antibiotic that will effectively treat the
infection We have developed state of the art nanotechnology that has miniaturized a microbiology lab and
hence enables bacterial detection and antibiotic resistance testing in the patientandapos s urine at the point of care
Thus physicians can prescribe the right antibiotic right away In this way the therapy outcome for the patients
will be dramatically improved and healthcare costs will be reduced
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Manufacturing and Formulation Process Development for a Prophylactic Cholera Phage Cocktail
- A first-in-class product for the clearance of high-risk human papillomaviruses
- A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance
- Optimization, Pharmacokinetics, and Efficacy of an IgG Protease for the Treatment of Immune Thrombocytopenia and Other IgG-Mediated Autoimmune Diseases
- Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients